The Cost to Treat Cholesterol Plummets, But Will It Last?

Every year, Express Scripts crunches the previous year's data to uncover payer spending trends. One of the most encouraging of those trends is the steep drop-off in spending on cholesterol-lowering drugs.

Last year, health care payers forked over 14% less for medications like statins that are designed to reduce bad cholesterol. That's a big decline given only spending on diabetes drugs eclipses spending on high blood cholesterol drugs.

However, before payers pop champagne corks, a new class of cholesterol fighting compounds are working their way through trials at Amgen (NASDAQ: AMGN  ) , Regeneron (NASDAQ: REGN  ) , and Pfizer (NYSE: PFE  ) that are likely to cause spending to spike in the future.

Source: Express Scripts.

Generics make it cheaper, for now
The decline in spending on cholesterol busting compounds is thanks in part to the expiration of patent exclusivity for some of the nation's best-selling drugs. The biggest of these drugs, Lipitor, racked up more than $125 billion in total sales for Pfizer (peaking at over $10 billion per year) before it lost patent exclusivity in 2011.

The widespread availability of generic statins is cutting into sales of those branded statins remaining on the market, including Merck's (NYSE: MRK  ) Vytorin and AstraZeneca's $5.6 billion a year Crestor (which goes off patent in 2016).

As a result, the unit cost for cholesterol-lowering drugs fell more than 12% last year as the percentage of scripts filled by generics rather than branded alternatives improved to better than three out of every four prescriptions.

Will spending spike?
The spending slide may shift back to a spike if a new class of cholesterol-fighting drugs known as PCSK9 inhibitors makes its way to market.

Statins encourage the liver to remove LDL from the bloodstream by reducing the production of a cholesterol-creating enzyme. This new class of drugs works by limiting PCSK9's production of a key protein that reduces the number of LDL receptors on cells responsible for eliminating LDL from the bloodstream.

Since the two have differing mechanism of action, doctors could prescribe them as an alternative to, or alongside, statins.

That's because statins have long been known to be imperfect solutions to lowering LDL. Statins can cause neurologic side affects like memory loss and muscle weakness in some patients, and other patients are simply resistant to them. Additionally, statins can increase PCSK9 expression in some patients, counteracting their LDL lowering ability.

Encouraging results
While the FDA has recently asked drug developers to start compiling data on neurological disorders that may be similar to those experienced by patients on statins, Amgen's AMG-145, or evolocumab, has posted solid results during trials. That has Amgen planning to file evolocumab for FDA approval later this year.

During phase 3 studies, more than 4,000 patients were treated with evolocumab, and on average, they saw their LDL drop significantly. In one study, evolocumab lowered LDL by 57% versus placebo. In another, matching up evolocumab with statin therapy lowered it by 75%.

Amgen is also studying the use of evolocumab alongside Merck's multi-billion dollar a year Zetia. Zetia is commonly dosed alongside statins to boast their effect, and Amgen has shown that using evolocumab with Zetia can have a dramatic LDL lowering effect versus using Zetia or evolocumab alone.

Regeneron and its development partner Sanofi (NYSE: SNY  )  are also working on their own PCSK9 drug, alirocumab. In studies, Regeneron and Sanofi report that alirocumab lowered LDL by 47% after 12 weeks.

Pfizer's RN316, or bococizumab, is another PCSK9 alternative that Pfizer thinks could prove very effective at tackling tough LDL, particularly in hard-to-treat patients. Bococizumab lowered LDL by 56% after 12 weeks during studies, and Pfizer kicked off a phase 3 trial last October.

Fool-worthy final thoughts
Last year, the American Heart Association recommended expanding the use of statins beyond those already showing signs of heart disease to those that may be at risk of developing heart disease based on factors like weight, age, and blood pressure. That is likely to signifciantly boost the patient population being prescribed LDL lowering drugs.

For now, the affect on spending by a bump in prescriptions won't be great, but if PCSK9 drugs become available, their ostensibly higher prices could blunt cost savings from the shift to generic statins, especially if the American Heart Associations' projection that roughly 40% of the population will suffer from some form of cardiovascular disease by 2030 prove correct.

Ultimately, the potential for these drugs is unknown, so here are 6 other ideas that may have more certainty
They said it couldn't be done. But David Gardner has proved them wrong time, and time, and time again with stock returns like 926%, 2,239%, and 4,371%. In fact, just recently, one of his favorite stocks became a 100-bagger. And he's ready to do it again. You can uncover his scientific approach to crushing the market and his six carefully chosen picks for ultimate growth instantly, because he's making this premium report free for you today. Click here now for access.

Read/Post Comments (2) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On April 14, 2014, at 11:58 PM, kdavis860 wrote:

    The article says statins can cause neurological problems and muscle weakness in some patients. It's hard to argue with "some", because 15 people out of a million is indeed "some", but my understanding is that the latest research on this says neither of these concerns is valid. Only four people in controlled studies have had the "delusional episodes" out of many tens of thousands of people, and some very good recent studies have decided the muscle pain thing is a myth.

  • Report this Comment On April 15, 2014, at 9:13 AM, 4mikie wrote:

    Since "high cholesterol" is mainly a "lifestyle disease", one can decrease cholesterol natually by getting more physical and lowering intake of animal meat and dairy products (milk, milk products, cheeses, eggs, and CERTAINLY stopping ALL consumption of partially-hydrogenated oil).Cholesterol medications are extremely hazardous to your health and -according to studies-work about 1% of the time!

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2909287, ~/Articles/ArticleHandler.aspx, 9/3/2015 12:50:05 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Todd Campbell

Todd has been helping buy side portfolio managers as an independent researcher for over a decade. In 2003, Todd founded E.B. Capital Markets, LLC, a research firm providing action oriented ideas to professional investors. Todd has provided insight to a variety of publications, including SmartMoney, Barron's, and CNN/fn.

Today's Market

updated 3 hours ago Sponsored by:
DOW 16,351.38 293.03 1.82%
S&P 500 1,948.86 35.01 1.83%
NASD 4,749.98 113.87 2.46%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/2/2015 3:59 PM
AMGN $152.29 Up +4.83 +3.28%
Amgen CAPS Rating: ****
MRK $52.98 Up +0.45 +0.86%
Merck & Co., Inc. CAPS Rating: ****
PFE $31.97 Up +0.61 +1.95%
Pfizer CAPS Rating: ****
REGN $518.78 Up +22.36 +4.50%
Regeneron Pharmace… CAPS Rating: ***
SNY $49.23 Up +1.12 +2.33%
Sanofi (ADR) CAPS Rating: *****